Apple Watch Ultra 2 and Series 9 Sales Pause Amid Dispute Over Blood Oxygen Technology

The Apple Watch Ultra 2 and Series 9 have been halted from sales due to a dispute over blood oxygen technology. This decision comes after the International Trade Commission (ITC) found that Apple had infringed on two patents related to the Apple Watch’s pulse oximeter feature. The dispute is with medical technology company Masimo, which has been fighting this battle since 2020.

The ITC’s ruling has led to a pause in sales of the Apple Watch Ultra 2 and Series 9, with Apple’s website and retail stores no longer offering these devices. However, third-party outlets such as Amazon and Best Buy will still have them available for purchase.

Apple has released a statement, expressing its disagreement with the order and stating that it is taking all necessary measures to ensure that the Apple Watch is available to customers. The company is also planning to file an appeal on December 26th.

This decision may make it more challenging for customers to find the latest models of the Apple Watch in the near future. However, Apple is hopeful that it can resolve the issue and return the Apple Watch Series 9 and Apple Watch Ultra 2 to customers in the United States as soon as possible.

In conclusion, the Apple Watch Ultra 2 and Series 9 have been halted from sales due to a dispute over blood oxygen technology. This decision has been made by the International Trade Commission (ITC) after finding that Apple had infringed on two patents related to the Apple Watch’s pulse oximeter feature. Apple is currently working on resolving the issue and plans to file an appeal on December 26th.